Cultures of embryonic day 17 (El7) rat adrenal and neonatal bovine adrenal cells were conditionally immor talized with the temperature-sensitive allele of SV40 large T antigen (tsTag) and chromaffin cell lines estab lished. Indicative of the adrenal chromaffin phenotype, these cells expressed immunoreactivity (ir) for tyro sine hydroxylase (TH), the first enzyme in the synthetic pathway for catecholamines. At permissive temperature in vitro (33°C), these chromaffin cells are proliferative, have a typical rounded chromaffin-like morphology, and contain detectable TH-ir. At nonpermissive temperature in vitro (39°C), these cells stop proliferating and express increased TH-ir. When these immortalized chromaffin cells were transplanted in the lumbar subarachnoid space of the spinal cord 1 week after a unilateral chronic constriction injury (CCI) of the rat sciatic nerve, they survived longer than 7 weeks on the pia mater around the spinal cord and continued to express TH-ir. Conversely, grafted chromaffin cells lost Tag-ir after transplant and Tag-ir was undetectible in the grafts after 7 weeks in the subarachnoid space. At no time did the grafts form tumors after transplant into the host animals. These grafted chromaffin cells also expressed immunoreactivities for the other catecholamine-synthesizing enzymes 7 weeks after grafting, including: dopamine-(3-hydroxylase (DpH) and phenylethanolamine-A'-methyltransferase (PNMT). The grafted cells also expressed detectable immunoreactivities for the opioid met-enkephalin (ENK), the peptide galanin (GAL), and the neurotransmit ters y-aminobutyric acid (GABA) and serotonin (5-HT). Furthermore, after transplantation, tactile and cold allodynia and tactile and thermal hyperalgesia induced by CCI were significantly reduced during a 2-8week period, related to the chromaffin cell transplants. The maximal antinociceptive effect occurred 1-3 weeks after grafting. Control adrenal fibroblasts, similarly immortalized and similarly transplanted after CCI, did not express any of the chromaffin antigenic markers, and fibroblast grafts had no effect on the allodynia and hyperalgesia induced by CCI. These data suggest that embryonic and neonatal chromaffin cells can be conditionally immortalized and will continue to express the phenotype of primary chromaffin cells in vitro and in vivo; grafted cells will ameliorate neuropathic pain after nerve injury and can be used as a homoge neous source to examine the mechanisms by which chromaffin transplants reverse chronic pain. The use of such chromaffin cell lines that are able to deliver antinociceptive molecules in models of chronic pain after nerve and spinal cord injury (SCI) offers a novel approach to pain management.
INTRODUCTION
Primary chromaffin cells have been used for trans plantation and delivery of therapeutic molecules into re cipients for a variety of therapeutic indications, includ ing pain, Parkinson's disease, traumatic brain injury, stroke, and depression (63) . Secretion of neurotransmit ters, neurotrophic factors, opioids, neuropeptides, excit atory amino acid antagonists, or other unknown sub stances from these cells has been demonstrated to effectively halt or reverse various disease processes (28) . Chromaffin cells from both human and bovine sources have been used in early stage clinical trials for the treatment of Parkinson's disease and chronic pain (77) .
However, a serious limitation in the widespread ap plication of this approach for the therapeutic application is the necessity of harvesting fresh cells from donors because chromaffin cells are mostly postmitotic. This approach is costly, time consuming, and inconvenient. In addition, the resultant cell preparation is obtained from different donors, possibly requiring complete safety screening for each batch of cells. In addition, this primary culture approach could result in different mix tures of cell types that are incompletely characterized and nonhomogeneous.
The generation of chromaffin cell lines would over come many of the limitations of primary chromaffin cell culture. However, past experience in other laboratories has indicated that, with the exception of tumor cell lines such as pheochromocytomas, chromaffin cell lines are difficult to generate. Pheochromocytoma cell lines are inappropriate for therapeutic use due to the great risk of unrestricted cell division and tumor formation (30) . Moreover, pheochromocytoma cell lines, such as the rat PC 12 line, may not behave as normal mature chromaffin cells, in that they appear to maintain or dedifferentiate to a less mature phenotype. For example, PC 12 cells synthesize dopamine and some norepinephrine, but only low levels of epinephrine, a principal catecholamine in mature chromaffin cells (27) . In support for this, these cells have also been found to lack detectable levels of phenylethanolamine-A f -methyltransferase (PNMT), which catalyzes the conversion of norepinephrine to epi nephrine (27) .
Several attempts have been made to generate immor talized chromaffin cell lines. Birren and Anderson (5) have reported v-myc immortalized sympathoadrenal pro genitor cell lines from embryonic rat adrenal glands. Suri et al. (75) have generated adrenal cell lines from tyrosine hydroxylase SV40 T antigen transgenic mice. However, like PC 12 cells, in both of these cases the immortalized cells generated produced dopamine and some norepinephrine, but not epinephrine, and lacked the synthetic enzyme PNMT.
An additional limitation using both of these ap proaches is that the immortalized cells generated are oncogenically transformed and continue to divide, creating a risk of tumorigenesis if transplanted into an immuneprivileged site such as the central nervous system. An exception to this in the v-myc immortalized lines is the differentiation of a small percentage of cells to postmi totic neurons. However, these postmitotic cells become NGF dependent and rapidly die in its absence (5) . Con ditional immortalization is a means to generate an im mortalized cell line that can later be disimmortalized to stop cell division. Several approaches for conditionally immortalizing cell lines have been described in the liter ature. One approach involves the use of the temperaturesensitive mutant of the SV40 large T antigen (tsTag) (26) and has been used successfully to conditionally im mortalize embryonic CNS neurons (23) . Using this ap proach, transfected cells undergo continual cell division at low temperature conditions (e.g., 32-34°C), but dif ferentiate and become postmitotic when the temperature is raised (37-39°C). The host CNS environment to re ceive these tsTag-immortalized cell lines has a tempera ture about 36-39°C, and transplantation allows the cells to cease proliferation and continue differentiation with out tumor formation. Thus, conditional immortalization with the tsTag construct incorporates the advantages of cell lines, including the convenience of growing large quantities that can be characterized and safety tested and the ability to genetically engineer in additional therapeu tic molecules, while reducing the disadvantages of tu mor cell lines.
Conditional immortalization of chromaffin cells us ing tsTag has recently been reported (16, 25) , and here we describe the use of subarachnoid grafted chromaffin cell lines in reducing pain. The preliminary data describ ing the use of these grafted cell lines for neuropathic pain have been recently reported (17) . This transplanta tion approach to chronic pain after nerve injury is ex pected to provide a useful model for the creation of sim ilarly derived human cell lines and their application to a strategy for the alleviation of chronic pain following hu man peripheral nerve and SCI.
MATERIALS AND METHODS

Primary Culture and Immortalization of Dissociated
Rat and Bovine Adrenals
Methods to culture chromaffin cells from rat embry onic adrenal tissue have been previously described (24) .
The generation and initial in vitro characterization of the immortalized rat and bovine cell lines used here for transplantation have been recently described (16, 25) . 
Chromaffin Clones
The methods for transplantation of similarly immor talized neuronal rat cell lines into the subarachnoid space of the lumbar spinal cord after nerve injury for pain relief has been described previously (15) . The chro maffin and fibroblast control cell lines were grown at permissive temperature (33°C) in CNS medium/10% FBS/125 pg/ml G418 as described previously (16, 80) . BrdU. Cells used for transplants and antibody stain ing were treated with 10 pm BrdU during proliferation for 3 days before transplantation and grafts were stained for BrdU posttransplantation as described previously (19) . The nucleic acid BrdU, followed by a anti-BrdU antibody (Becton Dickenson, Mountain View, CA), has been commonly used (84) to mark cell nuclei and,was used here to mark the surviving cells transplanted (68) in the subarachnoid space of the lumbar spinal cord.
Briefly, sections were rehydrated in DPBS buffer, fol lowed by 2 N HC1 for 30 min and rinsing with DPBS. grafts is a modification of methods described previously (2) . After removal from the vertebral column, cords were stored in fix for 12 h, 4°C, before paraffin embed-ding and thin sectioning. The anti-DpH antibody (1: 1000/DPBS; Chemicon) was incubated with TX-permeabilized (0.2%/DPBS) sections overnight at 4°C, fol lowed by an anti-rabbit peroxidase ABC reporter (Vec tor) and "VIP" substrate (Vector).
GABA. Methods for staining transplanted cells for GABA have been described previously (19) . The anti-GABA antibody (1:5000/DPBS; Incstar) was incubated with TX-permeabilized (0.2%/DPBS) sections overnight at 4°C, followed by an anti-rabbit peroxidase ABC re porter (Vector) and "VIP" substrate (Vector).
GAL. Some sections were also stained for GAL to assess whether the chromaffin grafts were able to syn thesize GAL during the course of the experiments. Anti body staining for GAL in the grafts is a modification of methods described previously (6, 10, 45, 46) . After re moval from the vertebral column, cords were stored in fix for 12 h, 4°C, before paraffin embedding and thin sectioning. The anti-GAL antibody (1:2000/DPBS; pH 7.4; Penninsula Labs-RAS7141) was incubated with TX-permeabilized (0.2%/DPBS) sections overnight at 4°C, followed by an anti-rabbit peroxidase ABC reporter (Vector) and "VIP" substrate (Vector).
ENK. Some sections were also stained for ENK to assess whether the chromaffin grafts were able to syn thesize enkephalin during the course of the experiments. Antibody staining for ENK in the grafts is a modifica tion of in vitro methods described previously (16) . After removal from the vertebral column, cords were stored in fix for 12 h, 4°C, before paraffin embedding and thin sectioning. The anti-ENK antibody (1:1000/DPBS; Pen insula Labs) was incubated with TX-permeabilized (0.2%/DPBS) sections overnight at 4°C, followed by an anti-rabbit peroxidase ABC reporter (Vector) and "VIP" substrate (Vector).
PNMT. Some sections were also stained for PNMT to assess whether the chromaffin grafts were able to syn thesize epinephrine during the course of the experi ments. Antibody staining for PNMT in the grafts is a modification of methods described previously (9) . After removal from the vertebral column, cords were stored in fix for 12 h, 4°C, before paraffin embedding and thin sectioning. The anti-PNMT antibody (1:1000/DPBS; In cstar) was incubated with TX-permeabilized (0.2%/ DPBS) sections overnight at 4°C, followed by an antirabbit peroxidase ABC reporter (Vector) and "VIP" sub strate (Vector).
Serotonin
(5-HT). Methods for staining for 5-HT were modified from those described elsewhere (20) .
Briefly, sections of lumbar spinal cord with transplants were permeabilized with 0.2% TX/DPBS for 10 min.
The anti-5HT antibody (1:5000; Incstar) was incubated with permeabilized sections overnight at 4°C, followed by an anti-rabbit peroxidase ABC reporter (Vector) and
"VIP" substrate (Vector).
Tag. In another set of grafted animals, sections were stained at various time points after transplant of rat and bovine chromaffin cell lines to determine if grafts con tinued to express Tag-ir at nonpermissive temperature in vivo, which would reflect the possibility of continued proliferation. Antibody staining for Tag in the grafts is a modification of the methods described for in vitro staining for Tag in the chromaffin cell lines (16) TH. Rat spinal cords were fixed weekly for survival and TH staining, 1-6 weeks after CCI and transplanta tion, by transcardial perfusion fixation by methods de scribed elsewhere (69) . Antibody staining for TH in the grafts is a modification of methods described previously (50, 74) . After removal from the vertebral column, cords were stored in fix for 12 h, 4°C, before paraffin embed ding and thin sectioning. The anti-TH antibody (1:5000/ DPBS; Chemicon) was incubated with TX-permeabil ized (0.2%/DPBS) sections overnight at 4°C, followed by an anti-rabbit peroxidase ABC reporter (Vector) and
"VIP" substrate (Vector). Every second section was stained for BrdU or TH and dehydrated, cleared, and mounted in Permamount after antibody staining.
Quantitation of Antigens in Chromaffin Grafts
Spinal cords were removed 7 weeks after grafting and nerve injury and stained for the antigens as described above. Sections that were immunopositive for BrdU de 
Chronic Constriction Injury (CCI)
The surgery to produce CCI was first described by Bennet and Xie (4). This model of injury has been used to test the effects of transplants to relieve pain-related behaviors (61) , and was subsequently used before trans plantation of chromaffin and control cells (15) . Under ketamine/xylazine anesthesia, the right common sciatic nerve was exposed at the level of the middle thigh by blunt dissection through the biceps femoris. Proximal to the nerve's trifurcation, a 5-7-mm length of nerve was freed of adhering tissue and four ligatures (4.0 chromic gut) were tied loosely around it with about 1-mm spac ing. Care was taken to tie the ligatures so that the diame ter of the nerve was barely constricted. The incision was closed in layers and the entire surgery was repeated, mi nus the ligatures, on the left side to create a sham-oper ated nerve.
Behavioral Testing
Testing Protocol. One week before CCI and trans plants, animals were acclimated and trained for 3 days on all behavioral tests, followed by a baseline measure of the tests described below 1 week before CCI. One
week following CCI and every week thereafter animals were retested. Animals to be transplanted were then in jected with either the control fibroblast or rat or bovine chromaffin cells. A third group of animals received CCI but no transplants and served as the CCI-alone control group. A fourth group of animals received neither CCI nor transplants and served as the naive control animals.
Behavioral testing was repeated for all animals once a week for 8 weeks following CCI and transplants. All animals used for behavioral testing were sacrificed after 8 weeks of testing.
Another group of animals used to examine survival of cells after CCI and transplantation was sacrificed weekly and was not included with those used for behav ioral testing.
Cold Allodynia.
Methods for testing the response to cold stimuli have been described elsewhere (4 were considered statistically significant.
RESULTS
Chronic Survival and TH Immunoreactivity in Grafted
Cells After Transplantation
Chronic survival of transplanted cells was evaluated in rat and bovine chromaffin cell grafts with anti-BrdU immunohistochemistry at weekly intervals after trans plant placement. Examples of transplant survival using BrdU-ir 7 weeks after grafting is seen in Figure 1 Tag-ir and were likely to be differentiating, rather than continuing to proliferate. The disappearance of Tag-ir in the chromaffin grafts is illustrated in Figure 2 . Both rat ( Fig. 2A-D) and bovine grafts ( Fig. 2E-H) were stained for Tag-ir at 3 days ( Fig. 2A, E ), 1 week (Fig. 2B, F with bis benzamide (Fig. 2D, H) .
D$H and PNMT Enzyme-ir in Grafted Cells After Transplantation
Transplanted chromaffin cells were evaluated in rat 
Other Antigens Expressed by Grafted Chromaffin Cells After Transplantation
Other likely antinociceptive molecules expressed by primary chromaffin cells, such as ENK (3, 43) , GAL 
Quantitation of Survival and Phenotypic Markers in Grafted Chromaffin Cells After Transplantation
Immunoreactivity for the catecholamine enzymes and other chromaffin phenotype markers illustrated above were quantified in chromaffin cell grafts 7 weeks after transplant and nerve injury, and the results are summa rized in Table 1 (bovine grafts) and Table 2 (rat grafts).
After 
Thermal Hyperalgesia After Transplants
The measure of sensitivity to noxious heat in animals after nerve injury and rat and bovine cell transplants is shown in Figure 5(A, B) . In control animals without sur gery or transplants, no difference was observed between 
Tactile Hyperalgesia After Transplants
The effects of transplants of rat and bovine chromaf fin and fibroblast cells on tactile hyperalgesia, or paw pinch, is shown in Figure 6(A, B) . Naive animals dem onstrated a similar sensitivity in each hindpaw, with the range of latency scores 8.0-13.0 in the left paw and 7.0-15.0 in the right paw. One week after CCI only, the maximum response to paw pinch was seen in the ligated hindpaw and this level of hypersensitivity continued throughout the 8 weeks after CCI. The range of raw la tency scores at 1 week after CCI for the ligated hindpaw 
Tactile Allodynia After Transplants
The effects of transplants of the rat and bovine chro maffin and fibroblast cells on mechanical allodynia after CCI are shown in Figure 7(A, B) . All animals were ex amined 1 week before CCI and for 8 weeks after CCI for foot withdrawal in response to stimulation with a graded series of von Frey hairs as described in Materials and Methods. A significant response appeared in the li gated hindpaw 1 week after CCI alone did not resolve during the 8 weeks after surgery. The near maximum nociceptive effect appeared in the ligated paw versus the nonligated paw at 1 week following CCI, with the range of raw latency scores of 0.025-0.675 g for the ligated paw and 1.22-3.55 g in the nonligated paw. At the same time period, the scores for the uninjured control animals varied from 1.20 to 3.60 g in either paw. However, 1 week after rat chromaffin cells were transplanted near the lumbar spinal cord after CCI, the mechanical sensi tivity began to resolve, with near normal absence of hy persensitivity by 8 weeks, compared to CCI alone. At this time period, the range of raw latency scores was 0.49-3.60 g in the ligated paw and 3.90-4.08 g in the nonligated paw. Three weeks after bovine chromaffin cells were transplanted near the lumbar spinal cord after CCI, the mechanical sensitivity began to resolve, with near normal absence of hypersensitivity by 8 weeks, compared to CCI alone. At this time period, the range of raw latency scores was 0.50-3.60 g in the ligated paw and 3.90-4.08 g in the nonligated paw. Transplants of the rat and bovine fibroblast cells had no significant effect on the induction of allodynia by CCI. At this same time period, 2-3 weeks after transplants of rat fibroblast cells, 3-4 weeks after CCI, the range of raw latency scores in the ligated paw was 0.030-0.69 g in the ligated paw and 1.20-3.60 g in the nonligated paw. Two to 3 weeks after transplants of bovine fibroblast cells, 3-4 weeks after CCI, the range of raw latency scores was 0.033-0.72 g in the ligated paw and 1.25-3.25 g in the nonligated paw.
Cold Allodynia After Transplants
The effects of transplants of the rat (Fig. 8A1 , Bl) and bovine (Fig. 8A2, B2 ) chromaffin and fibroblast cells on the frequency (Fig. 8A1, A2 ) and duration (Fig.  8B1, B2 ) of cold allodynia after CCI are shown in Fig  ure 8 . A measure of cold allodynia using hindpaw with drawal to a cold plate demonstrated a vigorous hyper sensitivity 1 week after the CCI alone that continually increased throughout 8 weeks after CCI, and never re turned to baseline. At 2 weeks after CCI, the range of latency scores was 10-47 hindpaw lifts, with a 12.5-80.0-s duration in the ligated hindpaw, for the CCI ani mals in Figure 8A1 and Bl. At 2 weeks after CCI, the range of latency scores was 10-36 hindpaw lifts, with 12.5-80.1-s duration in the ligated hindpaw, for the CCI animals in Figure 8A2 and B2. Both the number of hind paw lifts (Fig. 8A1, A2 ) and total duration of hindpaw Seven weeks after placing subarachnoid grafts of rat chromaffin cells, the RAD5.2 cells, which had been pretreated with 1 uM BrDU for 3 days in vitro during proliferation at 33°C before transplant, spinal cords were removed, and stained for BrdU, TH, GABA, 5-HT, ENK, and GAL. Only animals that demonstrated tactile and thermal allodynia and hyperalgesia 1 week after CCI were transplanted, and subsequently used for immunohistochemical evaluation. The data represent total number of cells per graft ± SEM stained for each antigen and the mean number per section ± SEM from three animals. week following the CCI, 1 day following behavioral testing. Animals were tested for hindpaw withdrawal in a paw pinch device once every week for 1 week before and 8 weeeks following CCI and before and after transplants. Only animals that demon strated tactile hyperalgesia 1 week after CCI were trans planted. The data reported are the mean ± SEM of the differ ence values for ligated paw minus the sham-operated paw of 14 animals in each group. Asterisks (*) indicate the chromaffin cell line transplants that differed significantly from the CCI condition at each time point: p < 0.01. withdrawal (Fig. 8B1, B2 ) were significantly reduced after transplantation of rat and bovine chromaffin cells near the lumbar spinal cord, with the reduction of sensi tivity beginning 1 week after transplant of chromaffin cells (2 weeks after CCI). The range of raw latency scores at this time point was 2-8 hindpaw lifts in the ligated paw, with no lifts in the nonligated paw, for the animals in Figure 8A1 week following the CCI, 1 day following behavioral testing. Animals were tested for hindpaw withdrawal to a graded series of von Frey hairs once every week for 1 week before and 8 weeks following CCI and before and after transplants. Only animals that dem onstrated tactile allodynia 1 week after CCI were transplanted. The data reported are the mean ± SEM of the difference scores for ligated paw minus the sham-operated paw of 14 animals in each group. Asterisks (*) indicate the chromaffin cell line transplants that differed significantly from the CCI condition at each time point: p < 0.01. paw withdrawals were similar to CCI alone. The range of latency scores was 13-40 hindpaw lifts and 8.8-136.9-s duration over 20 min in the ligated hindpaw at 1 week posttransplant for the animals in Figure 8A1 , and 11-49 hindpaw lifts and 26.8-200.2-s duration over 20 min in the ligated hindpaw for the animals in Figure  8A2 .
DISCUSSION
Transplants of primary chromaffin cells have been used in a variety of neurodegenerative diseases, includ ing chronic pain. There is an extensive literature describ ing the use of primary adrenal tissue and allografts, as well as dissociated chromaffin cultured cells, to reverse the behavioral hypersensitivity related to chronic pain that develops after peripheral sciatic nerve constriction (13, 28) , hindpaw injection of formalin (72) , laser-in duced ischemia of the spinal cord (85) , and excitotoxic chemical lesioning of the spinal cord (7) . The use of chromaffin grafts and the changes in the spinal environ ment near the dorsal horn after transplant is best charac terized with the use of the sciatic nerve constriction (CCI) model, where catecholamines and met-enkephalin synthesized and released by the chromaffin grafts (59, 60) are postulated to provide the antinociception in these models. However, the cell biology of these grafted chro maffin cells remains open to question, given the hetero geneity of cultured preparations from primary sources, as well as any deduction of the exact nature of possible antinociceptive molecules released by grafted cells in the various models of chronic neuropathic and neuro genic pain.
The initial characterization (16) of the rat and bovine chromaffin cell lines used here for transplant after con ditional immortalization with the tsTag construct de scribed the presence and regulation with glucocorticosteroids and cAMP activation of all the enzymes necessary for the identification of the chromaffin pheno type in vitro, using TH-, DpH-, and PNMT-ir in the cells as a marker for the noradrenergic and adrenergic pheno type of chromaffin cells. However, initial HPLC charac terization of these immortalized chromaffin cells did not suggest that these cells are able to synthesize catechola mines in vitro. It has been thought that to alter spinal biochemistry for antinociception after chromaffin trans plant requires that the chromaffin grafts be able to con stitutively produce the catecholamine neurotransmitters during their survival near the spinal cord (57) . Both the rat and bovine chromaffin cell lines express detectable TH and other catecholamine enzymes (16) when the cells are proliferating at permissive temperature in vitro, compared to the adrenal fibroblast control cell lines. The chromaffin cells also upregulate the TH protein expres sion during differentiation at nonpermissive temperature (39°C), when the mitotic drive from the large T antigen protein is off (22, 39) . It is possible that catecholamine synthesis may occur in vivo during differentiation in rat and bovine chromaffin cells after grafting, because the enzymes are expressed in surviving cells. Most surviv ing chromaffin grafted cells continue to contain TH-, DPH-, and PNMT-ir at 7 weeks after transplantation.
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-e-e-e-e-e-e-e-2 3 t transplant . Cold allodynia after CCI and transplants. The number of hindpaw withdrawals (Al, A2) or the total duration of hindpaw lifting (Bl, B2) in response to a cold plate over 20 min were counted once every week for 1 week before and 8 weeks following CCI and before and after transplants. Animals were either left unoperated (O) , given the CCI (•), or transplanted with rat RAD5.2 (Al, Bl), bovine BADA20 (A2, B2) (•) chromaffin cells, or rat (Al, A2) or bovine (Bl, B2) fibroblast cells (A) 1 week following the CCI, 1 day following behavioral testing. Only animals that demonstrated cold allodynia 1 week after CCI were transplanted. The data reported are the mean ± SEM of the difference values for ligated paw minus the sham-operated paw of 14 animals in each group. ANOVA indicated that the data were statistically significant. Asterisks (*) indicate the chromaffin cell line transplants that differed significantly from the CCI condition at each time point: p < 0.01.
Weeks after Chronic Constriction Injury
But it is not known at this time if grafts, which differen tiate in situ on the pial membrane, also synthesize and release catecholamines. If chromaffin grafts do not make significant levels of catecholamines, then the antinoci ception the grafts provide may be a result of other anti nociceptive molecules synthesized and released by the cells.
A number of other, possibly antinociceptive, mole cules are synthesized by primary chromaffin tissue: namely, GAL, GABA, and 5-HT (8, (32) (33) (34) 37, 55, 78) . Various other factors, such as chromogranins, the secre tory acidic proteins, are synthesized by chromaffin cells as well (78) . Histograin is found in high concentrations in chromaffin granules (44) , and may behave as an NMDA receptor antagonist. Recent studies indicate that an analog for the histogranin peptide, Serl-histogranin, markedly attenuated nociception after CCI (71) . These rat and bovine chromaffin grafts express many of these neurotransmitter and peptide immunoreactivities. The neurotransmitter GABA provided chronically by cell therapy (19) , or acutely by intrathecal administration (18) , is able to reverse neuropathic pain after nerve in jury. Similarly, chronic delivery of 5-HT from cell grafts (15) provides antinociception after CCI. The peptide GAL, delivered into the intrathecal space after nerve in jury, is also associated with antinociception (81) . The opioid ENK production by primary chromaffin grafts has been postulated as the most likely antinociceptive molecule synthesized by chromaffin cells (51) . In creased CSF levels of ENK have been demonstrated with subarachnoid chromaffin grafts in rats (59) and hu mans (58) . Transplants of chromaffin cell lines express ENK-ir ( Figs. 4 and 5) in vivo, and treatment with glucocorticosteroids, such as dexamethasone, upregulates ENK expression in these same cell lines with differenti ation in vitro (16) . A similar scenario may take place in vivo, with glucocorticosteroids regulating the cellular maturity, survival, and expression of various antinoci ceptive molecules in the grafts.
Dexamethasone is known to decrease NGF mRNA and synthesis in many types of astrocytes and fibroblasts in vitro (35, 48, 49) , while serum increases NGF produc tion from fibroblasts (35) . These studies suggest that the rat and bovine chromaffin cell lines that were prolifer ated in the presence of both dexamethasone and cocultured with fibroblasts were presumably inhibited from a switch to a neuronal phenotype. Because these cell lines might be dependent on other factors released from fibro blasts, they are not likely to be NGF dependent in the presence of dexamethasone and behave as mature chro maffin cells. Although the presence of corticoid recep tors has not been assayed in these chromaffin cell lines, they are presumed to be present and functional, because the cells respond with increased enzyme expression when dexamethasone is included during the differentia tion paradigm. How this in vitro alteration in adrenergic and noradrenergic phenotype with dexamethasone stim ulation might affect transplanted conditionally immortal ized chromaffin cell is not known, but presumably glu cocorticoid levels are adequate in the CNS (14) to ensure a chromaffin phenotype in differentiated grafts.
A necessary criteria for successful grafting of immor talized chromaffin cell lines for the reversal of behav ioral hypersensitivity after nerve injury is the actual chronic survival and expression of the chromaffin phe notype of grafts at the transplant location, the subarach noid space, near the lumbar spinal cord, where the affer ent fibers of the sciatic nerve enter the dorsal horn. Here, substantial numbers of the chromaffin cells survived at least 7 weeks after transplant into the spinal subarach noid space, with the cells attached to the cord several segments, perispinally, rostral and caudal to the trans plant site. With continued staining for TH-, D(3H-, PNMT-, GABA-, ENK-, and 5-HT-ir in most of the sur viving chromaffin cells throughout the experiment, it is possible or likely that the grafts may act as a supply for various inhibitory neurotransmitters, peptides, and opi oids, or other molecules from the chromaffin "trophic cocktail" synthesized by adrenal medullary chromaffin cells (78) , at least with a localized supply near the dorsal horn and lumbar spinal cord. Although it is not known what the transplant time "window" might be that is re quired for successful reversal of chronic pain by cell grafts, the chromaffin grafts are placed at a similar time point after nerve injury as has been done with primary chromaffin cells. It is likely that even if nociceptive sub stances supplied by the grafts are low, it is sufficient to affect the local spinal biochemistry. It is interesting to note the apparent "hypoalgesia" induced by cell grafts in the measure of thermal and tactile hyperalgesia. There is no current explanation for such a phenomenon and all cell therapies after CCI, including primary chromaffin grafts, seem to induce this "overshoot." However, the affected animals do not behave abnormally or exhibit any paralysis in the hindlimb. Primary chromaffin cell grafts recover the endogenous dorsal horn GABA sys tem after nerve injury and transplants, and there is no evidence that the endogenous spinal GABA system reaches anything but normal levels after chromaffin cell grafting (36) . Returning the balance of inhibitory tone at the dorsal horn may directly, through release of antinoci ceptive substances from chromaffin grafts into the CSF, or indirectly, by modulating the ascending signal to higher supraspinal centers, recover the spinal systems. Alternative placement of grafts at intracerebral or intra ventricular locations might significantly alter the rate of the reversal of nociception, and this strategy is currently being examined as well as analysis of the GABAergic content and changes in supraspinal centers after lumbar grafts of chromaffin cell lines after nerve and SCI.
A related issue for survival of chronic transplants with the substitution of immortalized for primary chro maffin cells is the use of xenogeneic bovine cells, such as the BADA.20 cell line used here. Primary bovine chromaffin cells that have been freed of endothelial and passenger, nonchromaffin, cells do not stimulate rat Tcell proliferative responses in vitro (12), do not require exogenous trophic factors for at least 8 weeks of robust survival in the rat subarachnoid location (47) , and shortterm immunosuppression after grafting in rats with cyclosporine A was sufficient for at least I year of sur vival and expression of the chromaffin cell phenotype (54) . The bovine BADA.20 chromaffin graft demon strated easily detectable cell numbers after 7 weeks, and such results are merely suggestive and likely to be an extreme underestimation of absolute cell numbers.
No animal in these studies developed tumors at the site of grafting over the 2-month period with the chro maffin cell lines containing the oncogenic Tag construct. The temperature-sensitive large T antigen used for im mortalization rapidly degrades at nonpermissive temper ature (38, 39, 76) . Given the conclusions that the Tag pro tein expression, mRNA levels for Tag and mitotic drive is absent after a short differentiation time (16) in vitro, and with the decrease of Tag-ir in chromaffin transplants after differentiation (Fig. 2) , the immortalized chromaf fin cell lines are not likely to be proliferative in vivo. Even if there is an initial cell division or two after graft ing, the intensity of the BrdU-ir (from pretransplant cell treatment) does not diminish in the grafts, suggesting no dilution of signal (which would represent cell division in the grafts over time). As well, the total cell counts in the grafts at 8 weeks represents >3% of the 10 6 cells injected. These observations, along with the data that show the disappearance of Tag-ir over time after trans plant in vivo, and as reported in vitro (16) , strongly sug gest that conditionally immortalized cell lines would be safe for use in humans. However, our laboratory is pur suing alternative immortalization/disimmortalization ap proaches to create stable cell lines for use with cell ther apy to ensure that such an approach is practical. This technology involves excising the Tag oncogene before transplant, retaining and enhancing the cell phenotype (31) . Others have concluded (39) that differentiation, at nonpermissive temperature, of tsTag-cells does not neg atively alter the protein-synthesizing capacity from that of the cells grown at permissive temperature, and cer tainly that seems to be true of these chromaffin cell lines in vitro (16) . Here, the grafted cell lines display a mature chromaffin phenotype, expressing many of the markers found in primary cultured and transplanted chromaffin cells.
Presumably, subarachnoid transplants of primary rat and xenogeneic bovine chromaffin cells reduce pain sen sitivity after sciatic nerve injury through the release and diffusion of opioid peptides, and possibly catechola mines, from the grafts into regions of the CNS sites that modulate pain (60, 65, 66, 79) . The dorsal horn contains a high density of opiate receptors as well as enkephalinergic interneurons (42), with intrathecal morphine eliciting potent analgesia (83) . There is a high density of norad renergic fibers in the spinal dorsal superficial laminae, and similar to morphine, intrathecal noradrenergic ago nists produces analgesia (53) , while the blockade of nor adrenergic receptors in the spinal cord produces an in creased sensitivity to noxious stimuli (64, 67) . Opioid peptides and catecholamines may act synergistically to induce their effects (82) . With the simultaneous pres ence of both opioid-ir and inhibitory neurotransmitter enzyme-ir 7 weeks after grafting with nerve injury in both rat and bovine chromaffin transplants, it is possible that the grafts are synthesizing and, presumably, secre ting or releasing one or both neuroactive substances throughout the time course of sensory testing.
In summary, immortalized chromaffin cell lines can be used as a potentially infinite homogeneous source for grafting and pain relief. The potential for tumor forma tion is not likely, with the decreased presence and activ ity of the Tag protein over 2 months after transplanta tion. Grafts are not rejected, even xenografts with shortterm immunosuppression, and the chromaffin cell phe notype is expressed when cells are attached to the pial membrane in the subarachnoid space. This initial study provides evidence that conditionally immortalized pri mary cells used for cellular therapy can function as bio logic "minipumps" after grafting and provide a model for the development of cell lines in the attenuation of chronic pain.
